Chickasaw Capital Management LLC Sells 685 Shares of Johnson & Johnson (NYSE:JNJ)

Chickasaw Capital Management LLC lowered its stake in Johnson & Johnson (NYSE:JNJGet Rating) by 3.5% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 18,888 shares of the company’s stock after selling 685 shares during the period. Johnson & Johnson accounts for approximately 0.2% of Chickasaw Capital Management LLC’s holdings, making the stock its 29th biggest holding. Chickasaw Capital Management LLC’s holdings in Johnson & Johnson were worth $3,337,000 as of its most recent SEC filing.

Other large investors have also added to or reduced their stakes in the company. TD Capital Management LLC bought a new stake in Johnson & Johnson in the third quarter valued at $48,000. Cowa LLC bought a new stake in Johnson & Johnson in the third quarter valued at $58,000. Legend Financial Advisors Inc. purchased a new position in Johnson & Johnson during the third quarter valued at $59,000. Adirondack Retirement Specialists Inc. purchased a new position in Johnson & Johnson during the third quarter valued at $67,000. Finally, Heritage Wealth Management LLC purchased a new position in Johnson & Johnson during the second quarter valued at $84,000. Institutional investors own 67.94% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts have commented on JNJ shares. SVB Leerink lowered their price objective on Johnson & Johnson from $194.00 to $186.00 and set an “outperform” rating for the company in a research report on Friday, January 20th. Guggenheim started coverage on Johnson & Johnson in a research report on Tuesday, February 28th. They set a “neutral” rating and a $161.00 price objective for the company. Atlantic Securities raised their price objective on Johnson & Johnson from $160.00 to $168.00 and gave the company a “neutral” rating in a research report on Wednesday, January 25th. Citigroup lifted their price target on Johnson & Johnson from $198.00 to $205.00 and gave the stock a “buy” rating in a research report on Monday, December 12th. Finally, Piper Sandler lowered their price target on Johnson & Johnson from $55.00 to $52.00 in a research report on Monday, February 6th. Seven investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from, the stock currently has an average rating of “Moderate Buy” and an average price target of $174.73.

Insider Buying and Selling at Johnson & Johnson

In other Johnson & Johnson news, insider James D. Swanson sold 1,062 shares of the business’s stock in a transaction dated Monday, March 6th. The stock was sold at an average price of $154.66, for a total transaction of $164,248.92. Following the completion of the sale, the insider now directly owns 9,215 shares in the company, valued at approximately $1,425,191.90. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Corporate insiders own 0.35% of the company’s stock.

Johnson & Johnson Price Performance

Shares of NYSE:JNJ opened at $152.38 on Friday. Johnson & Johnson has a fifty-two week low of $150.71 and a fifty-two week high of $186.69. The business has a 50-day simple moving average of $161.97 and a two-hundred day simple moving average of $167.91. The company has a debt-to-equity ratio of 0.35, a quick ratio of 0.77 and a current ratio of 0.99. The firm has a market cap of $396.84 billion, a price-to-earnings ratio of 22.61, a price-to-earnings-growth ratio of 2.65 and a beta of 0.54.

Johnson & Johnson (NYSE:JNJGet Rating) last issued its earnings results on Tuesday, January 24th. The company reported $2.35 earnings per share for the quarter, topping analysts’ consensus estimates of $2.22 by $0.13. Johnson & Johnson had a return on equity of 35.76% and a net margin of 18.90%. The business had revenue of $23.71 billion during the quarter, compared to analyst estimates of $23.90 billion. During the same quarter in the previous year, the firm earned $2.13 EPS. Johnson & Johnson’s revenue was down 4.4% on a year-over-year basis. On average, analysts expect that Johnson & Johnson will post 10.5 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Tuesday, March 7th. Shareholders of record on Tuesday, February 21st were paid a dividend of $1.13 per share. The ex-dividend date of this dividend was Friday, February 17th. This represents a $4.52 dividend on an annualized basis and a dividend yield of 2.97%. Johnson & Johnson’s dividend payout ratio is currently 67.06%.

About Johnson & Johnson

(Get Rating)

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and MedTech. The Consumer Health segment includes products focused on personal healthcare used in the Skin Health/Beauty, Over-the-Counter medicines, Baby Care, Oral Care, Women’s Health and Wound Care markets.

Featured Stories

Want to see what other hedge funds are holding JNJ? Visit to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJGet Rating).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with's FREE daily email newsletter.